Radiopharm Theranostics (RAD) Registration filing summary

Company overview and business model

• Focuses on developing and commercializing radiopharmaceutical platforms for therapeutic and diagnostic use in precision oncology, targeting radiosensitive solid tumors with high mortality rates.

• Pipeline includes six licensed platform technologies and a joint venture with MD Anderson for novel radiopharmaceutical products.

• Maintains partnerships with nuclear medicine suppliers and prestigious institutions to secure isotopes and expand clinical assets.

• Pursues global intellectual property protection and regulatory approvals in the US, EU, UK, China, Japan, Australia, and Canada.

• Operates as a foreign private issuer, benefiting from reduced US disclosure requirements.

Financial performance and metrics

• Completed a private placement in October 2025, raising approximately A$35 million by issuing 1,166,666,667 ordinary shares.

• As of June 30, 2025, pro forma cash and cash equivalents would be A$86.5 million after the private placement and full utilization of the offering.

• Public float as of October 17, 2025, was approximately $67.4 million.

Use of proceeds and capital allocation

• Net proceeds from the offering will fund drug candidate development and general corporate purposes, including potential acquisitions, joint ventures, and strategic transactions.

• Management retains broad discretion over allocation and timing of expenditures.